Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec has received €2.5m milestone payment under the research collaboration with Boehringer Ingelheim.
Subscribe to our email newsletter
The milestone was triggered as a result of the transition of an oncology programme into pre-clinical profiling.
Evotec chief operating officer Dr Mario Polywka said under the alliance with Boehringer Ingelheim, Evotec achieved seventeenth milestone.
"We are pleased the collaborative efforts of teams from Evotec and Boehringer Ingelheim continue to show success in progressing compounds towards the clinic," Dr Polywka added.
Evotec entered into a multi-year, multi-target drug discovery alliance with Boehringer in 2004 to develop preclinical development candidates for the treatment of various disease areas covering CNS, inflammation, cardiometabolic and respiratory diseases.
As per the agreement, Boehringer is responsible for clinical development, manufacturing and commercialization of the compounds identified while Evotec earns ongoing research payments and preclinical milestones.